Literature DB >> 10713122

HER-2/neu blocks tumor necrosis factor-induced apoptosis via the Akt/NF-kappaB pathway.

B P Zhou1, M C Hu, S A Miller, Z Yu, W Xia, S Y Lin, M C Hung.   

Abstract

Overexpression of HER-2/neu correlates with poor survival of breast and ovarian cancer patients and induces resistance to tumor necrosis factor (TNF), which causes cancer cells to escape from host immune defenses. The mechanism of HER-2/neu-induced TNF resistance is unknown. Here we report that HER-2/neu activates Akt and NF-kappaB without extracellular stimulation. Blocking of the Akt pathway by a dominant-negative Akt sensitizes the HER-2/neu-overexpressing cells to TNF-induced apoptosis and inhibits IkappaB kinases, IkappaB phosphorylation, and NF-kappaB activation. Our results suggested that HER-2/neu constitutively activates the Akt/NF-kappaB anti-apoptotic cascade to confer resistance to TNF on cancer cells and reduce host defenses against neoplasia.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10713122     DOI: 10.1074/jbc.275.11.8027

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  101 in total

1.  HER2 (neu) signaling increases the rate of hypoxia-inducible factor 1alpha (HIF-1alpha) synthesis: novel mechanism for HIF-1-mediated vascular endothelial growth factor expression.

Authors:  E Laughner; P Taghavi; K Chiles; P C Mahon; G L Semenza
Journal:  Mol Cell Biol       Date:  2001-06       Impact factor: 4.272

Review 2.  Androgens and prostate cancer.

Authors:  Alan I So; Antonio Hurtado-Coll; Martin E Gleave
Journal:  World J Urol       Date:  2003-10-29       Impact factor: 4.226

Review 3.  Control of oncogenesis and cancer therapy resistance by the transcription factor NF-kappaB.

Authors:  A S Baldwin
Journal:  J Clin Invest       Date:  2001-02       Impact factor: 14.808

4.  Light activation of the insulin receptor regulates mitochondrial hexokinase. A possible mechanism of retinal neuroprotection.

Authors:  Ammaji Rajala; Vivek K Gupta; Robert E Anderson; Raju V S Rajala
Journal:  Mitochondrion       Date:  2013-08-30       Impact factor: 4.160

Review 5.  The use of nanoparticulates to treat breast cancer.

Authors:  Xiaomeng Tang; Welley S Loc; Cheng Dong; Gail L Matters; Peter J Butler; Mark Kester; Craig Meyers; Yixing Jiang; James H Adair
Journal:  Nanomedicine (Lond)       Date:  2017-09-04       Impact factor: 5.307

6.  14-3-3ζ loss impedes oncogene-induced mammary tumorigenesis and metastasis by attenuating oncogenic signaling.

Authors:  Sonali Joshi; Jun Yang; Qingfei Wang; Ping Li; Hai Wang; Qingling Zhang; Yan Xiong; Brian F Pickering; Jan Parker-Thornburg; Richard R Behringer; Dihua Yu
Journal:  Am J Cancer Res       Date:  2017-08-01       Impact factor: 6.166

7.  Estrogen withdrawal-induced NF-kappaB activity and bcl-3 expression in breast cancer cells: roles in growth and hormone independence.

Authors:  M A Christine Pratt; Tanya E Bishop; Dawn White; Gordon Yasvinski; Michel Ménard; Min Ying Niu; Robert Clarke
Journal:  Mol Cell Biol       Date:  2003-10       Impact factor: 4.272

8.  14-3-3 sigma positively regulates p53 and suppresses tumor growth.

Authors:  Heng-Yin Yang; Yu-Ye Wen; Chih-Hsin Chen; Guillermina Lozano; Mong-Hong Lee
Journal:  Mol Cell Biol       Date:  2003-10       Impact factor: 4.272

9.  Nephrin and CD2AP associate with phosphoinositide 3-OH kinase and stimulate AKT-dependent signaling.

Authors:  Tobias B Huber; Björn Hartleben; Jeong Kim; Miriam Schmidts; Bernhard Schermer; Alexander Keil; Lotti Egger; Rachel L Lecha; Christoph Borner; Hermann Pavenstädt; Andrey S Shaw; Gerd Walz; Thomas Benzing
Journal:  Mol Cell Biol       Date:  2003-07       Impact factor: 4.272

10.  External control of Her2 expression and cancer cell growth by targeting a Ras-linked coactivator.

Authors:  Shinichi Asada; Yongmun Choi; Masaki Yamada; Shao-Chun Wang; Mien-Chie Hung; Jun Qin; Motonari Uesugi
Journal:  Proc Natl Acad Sci U S A       Date:  2002-09-19       Impact factor: 11.205

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.